Literature DB >> 17513196

Comorbidity implications in brain disease: neuronal substrates of symptom profiles.

Tomas Palomo1, Richard J Beninger, Richard M Kostrzewa, Trevor Archer.   

Abstract

The neuronal substrates underlying aspects of comorbidity in brain disease states may be described over psychiatric and neurologic conditions that include affective disorders, cognitive disorders, schizophrenia, obsessive-compulsive disorder, substance abuse disorders as well as the neurodegenerative disorders. Regional and circuitry analyses of biogenic amine systems that are implicated in neural and behavioural pathologies are elucidated using neuroimaging, electrophysiological, neurochemical, neuropharmacological and neurobehavioural methods that present demonstrations of the neuropathological phenomena, such as behavioural sensitisation, cognitive impairments, maladaptive reactions to environmental stress and serious motor deficits. Considerations of neuronal alterations that may or may not be associated with behavioural abnormalities examine differentially the implications of discrete areas within brains that have been assigned functional significance; in the case of the frontal lobes, differential deficits of ventromedial and dorsolateral prefrontal cortex may be associated with different aspects of cognition, affect, remission or response to medication thereby imparting a varying aspect to any investigation of comorbidity.

Entities:  

Mesh:

Year:  2007        PMID: 17513196     DOI: 10.1007/BF03033897

Source DB:  PubMed          Journal:  Neurotox Res        ISSN: 1029-8428            Impact factor:   3.911


  225 in total

Review 1.  Memory--a century of consolidation.

Authors:  J L McGaugh
Journal:  Science       Date:  2000-01-14       Impact factor: 47.728

2.  Regional cerebral blood flow in monozygotic twins discordant and concordant for schizophrenia.

Authors:  K F Berman; E F Torrey; D G Daniel; D R Weinberger
Journal:  Arch Gen Psychiatry       Date:  1992-12

Review 3.  The etiopathogenesis of schizophrenias.

Authors:  J Kornhuber; J Wiltfang; S Bleich
Journal:  Pharmacopsychiatry       Date:  2004-11       Impact factor: 5.788

Review 4.  Cognitive impairment and fMRI in major depression.

Authors:  K Ebmeier; E Rose; D Steele
Journal:  Neurotox Res       Date:  2006-10       Impact factor: 3.911

Review 5.  Inflammation and depression: is there a causal connection with dementia?

Authors:  B E Leonard; A Myint
Journal:  Neurotox Res       Date:  2006-10       Impact factor: 3.911

6.  Can't shake that feeling: event-related fMRI assessment of sustained amygdala activity in response to emotional information in depressed individuals.

Authors:  Greg J Siegle; Stuart R Steinhauer; Michael E Thase; V Andrew Stenger; Cameron S Carter
Journal:  Biol Psychiatry       Date:  2002-05-01       Impact factor: 13.382

7.  Synaptic pathology in the anterior cingulate cortex in schizophrenia and mood disorders. A review and a Western blot study of synaptophysin, GAP-43 and the complexins.

Authors:  S L Eastwood; P J Harrison
Journal:  Brain Res Bull       Date:  2001-07-15       Impact factor: 4.077

8.  Expression of serotonin 5-HT(2A) receptors in the human cerebellum and alterations in schizophrenia.

Authors:  S L Eastwood; P W Burnet; R Gittins; K Baker; P J Harrison
Journal:  Synapse       Date:  2001-11       Impact factor: 2.562

9.  Dopamine-mediated modulation of odour-evoked amygdala potentials during pavlovian conditioning.

Authors:  J Amiel Rosenkranz; Anthony A Grace
Journal:  Nature       Date:  2002-05-16       Impact factor: 49.962

10.  Activated human microglia produce the excitotoxin quinolinic acid.

Authors:  M G Espey; O N Chernyshev; J F Reinhard; M A Namboodiri; C A Colton
Journal:  Neuroreport       Date:  1997-01-20       Impact factor: 1.837

View more
  1 in total

1.  Behavioural supersensitivity following neonatal 6-hydroxydopamine: attenuation by MK-801.

Authors:  T Archer; Anders Fredriksson
Journal:  Neurotox Res       Date:  2007-09       Impact factor: 3.911

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.